Work

Effectiveness and Safety Outcomes of SGLT2 Inhibitors in Type 2 Diabetes and Use of Drugs with Nephrotoxic Potential

Year: 2024
Type: article
Study design: Observational Study
Abstract: Sodium Glucose Cotransporter 2 inhibitors (SGLT2is) improve the cardiovascular and renal outcomes in patients with Type 2 diabetes (T2D). However, there has been limited evidence on the usage pattern of drugs with nephrotoxic potential (NxP) and the potential offsetting of SGLT2i's renal benefits by such drugs. This dissertation aims to bridge these gaps by examining the trajectories of the use of drugs with NxP and the comparative cardiovascular, safety, and renal outcomes of SGLT2i versus DPP4 inhibitors (DPP4is) in Medicare beneficiaries with T2D. Chapter 3 examined the use patterns of drugs with NxP among T2D patients following the initiation of SGLT2i therapy. It identified distinct trajectories of use of drugs with NxP, with 53.9%, 21.8% and 24.3% of patients demonstrating low, high and no use of these drugs. The study also found patient demographics and clinical factors were associated with the drug usage patterns. In Chapter 4, we compared the cardiovascular and safety outcomes of SGLT2i versus DPP4i in T2D patients. The findings demonstrated that SGLT2is are associated with a decreased risk of hospitalized heart failure, major adverse cardiovascular events, alongside a favorable safety profile compared to DPP4is. Finally, in Chapter 5, we examined the effects of concurrent use of drug with NxP and SGLT2is on renal outcomes in T2D patients without a history of chronic kidney disease (CKD). We found that SGLT2is were associated with a lower risk of CKD and end-stage renal disease, and these benefits persisted regardless of the use of NxP drugs. Furthermore, a higher number of drugs with NxP used was associated with an increased risk of CKD, underscoring the importance of cautious NxP drug use in T2D patients. The findings presented in this dissertation fill crucial gaps in the literature, suggesting that SGLT2i therapy not only provides substantial cardiovascular benefits and a favorable safety profile, but also mitigates renal risk, even in the presence of use of drugs with NxP. These insights highlight the importance of SGLT2is in the management of T2D, guiding the development of treatment strategies that effectively reduce renal risk while enhancing overall treatment efficacy.
Author: Yang, Lanting
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W6981358623
FWCI:
Cites: 194
Cited by:
Related to: 9